{"product_id":"si-bone-pestle-analysis","title":"SI-Bone PESTLE Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eYour Shortcut to Market Insight Starts Here\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eOur PESTLE Analysis for SI-Bone reveals how political shifts, reimbursement trends, and rapid tech innovation are shaping its market opportunities and regulatory risks; ideal for investors and strategists seeking a concise external view. Purchase the full report to access detailed, actionable insights and ready-to-use slides that accelerate smarter decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eolitical factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealthcare Reform and Policy Shifts\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe US federal healthcare policy landscape drives access to elective orthopedic care; Medicare\/Medicaid and ACA changes reshape patient eligibility for sacroiliac joint procedures. As of late 2025, roughly 9.3% of adults reported being uninsured, affecting procedure volumes; policy shifts expanding enrollment could raise addressable market for iFuse by millions. SI-BONE must secure coverage policies and favorable coding\/ reimbursement to protect revenue and utilization.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernment Reimbursement Legislation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePolitical pressure on Medicare and Medicaid often drives reimbursement volatility for minimally invasive surgeries; CMS cut rates for certain device-intensive procedures by up to 3.5% in 2024, directly affecting SI-BONE revenue per case.\u003c\/p\u003e\n\u003cp\u003eCongressional and CMS rulemaking shape CPT coding and hospital payment bundles that justify high-end implants; unclear coding for sacroiliac fusion has limited uptake and reduced average selling price realization.\u003c\/p\u003e\n\u003cp\u003eSI-BONE invests in sustained advocacy and payer engagement—company disclosed 2024 selling, general and administrative expenses of $93M—reflecting lobbying and reimbursement strategy costs to counter government cost-containment policies.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInternational Trade and Tariff Policies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAs a global distributor, SI-BONE is vulnerable to US tariff changes and trade agreements affecting medical-grade titanium; a 10% tariff hike on key imports could raise COGS materially given titanium accounts for ~18% of implant materials costs. Political tensions with manufacturing hubs like Taiwan\/China risk shipment delays—global trade disruptions in 2023 caused average lead-time increases of 22%. By end-2025 SI-BONE must embed geopolitical risk premiums into sourcing and expansion models.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOpioid Crisis Mitigation Initiatives\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGovernment initiatives to curb opioid misuse—opioid-related overdose deaths reached ~80,000 in the US in 2021 and remained elevated through 2024—have increased funding and policy support for non-pharmacologic chronic pain treatments, favoring surgical options like SI-BONE’s sacroiliac fusion.\u003c\/p\u003e\n\u003cp\u003ePolicies reducing opioid prescriptions (US opioid prescribing declined ~40% from 2012–2022) create reimbursement and referral advantages for SI-BONE, aligning company offerings with public health priorities and easing engagement with health departments and regulators.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eOpioid overdose deaths ~80,000 (2021); sustained crisis through 2024\u003c\/li\u003e\n\u003cli\u003eOpioid prescribing down ~40% since 2012\u003c\/li\u003e\n\u003cli\u003ePolicy\/funding tilt toward non-opioid interventions benefits SI-BONE\u003c\/li\u003e\n\u003cli\u003eStrategic advantage for reimbursement and regulatory support\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Harmonization Efforts\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cppolitical moves toward harmonizing fda and ema device standards could shorten si-bone us-eu market entry timelines by an estimated months while shifts still pair streamlined pathways with increased post-market surveillance higher compliance costs additional annual qa spend\u003e\n\u003cpnavigating multi-jurisdictional political requirements remains essential for si-bone to protect us and eu revenue streams of sales sustain global competitiveness amid rising regulatory alignment scrutiny.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePotential 6–12 month faster approvals\u003c\/li\u003e\n\u003cli\u003eEstimated $2–5M incremental annual compliance costs\u003c\/li\u003e\n\u003cli\u003e~40% of 2024 revenue exposed to US\/EU regulatory changes\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pnavigating\u003e\u003c\/ppolitical\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePolicy cuts, opioid tailwinds and titanium risk shape iFuse growth amid $93M advocacy spend\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eFederal coverage changes, CMS reimbursement cuts (up to 3.5% in 2024) and CPT coding uncertainty constrain iFuse uptake; 2024 SG\u0026amp;A $93M underscores advocacy costs. Opioid policy tailwinds (opioid prescribing down ~40% since 2012; ~80,000 OD deaths in 2021) favor non-opioid surgical options. Tariff\/geopolitical risks could raise COGS (titanium ~18% of implant material cost); US\/EU rules affect ~40% of 2024 revenue.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCMS cut (2024)\u003c\/td\u003e\n\u003ctd\u003eup to 3.5%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSG\u0026amp;A (2024)\u003c\/td\u003e\n\u003ctd\u003e$93M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOpioid prescribing decline\u003c\/td\u003e\n\u003ctd\u003e~40% (2012–2022)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOpioid deaths (2021)\u003c\/td\u003e\n\u003ctd\u003e~80,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTitanium share of implant materials\u003c\/td\u003e\n\u003ctd\u003e~18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue exposed to US\/EU\u003c\/td\u003e\n\u003ctd\u003e~40%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eExplores how macro-environmental forces uniquely impact SI-Bone across Political, Economic, Social, Technological, Environmental, and Legal dimensions, with data-backed trends and forward-looking insights to identify risks and opportunities for executives, investors, and strategists.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise PESTLE summary for SI-Bone that highlights regulatory, reimbursement, technological, market, economic, and social factors—designed for quick insertion into presentations or team briefings to streamline external risk and opportunity discussions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eE\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003economic factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInflationary Pressure on Manufacturing Costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePersistent inflation through 2025 increased costs of specialized titanium alloys and precision machining by about 8–12%, while skilled labor rates rose roughly 6% year-over-year; SI-BONE must absorb these input cost increases without materially raising iFuse pricing to hospitals.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInterest Rate Environment and Capital Access\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe prevailing interest rate environment in late 2025—US Fed funds at ~5.25–5.50%—raises SI-BONE’s cost of capital, making debt-funded R\u0026amp;D more expensive and potentially slowing expansion plans.\u003c\/p\u003e\n\u003cp\u003eHigh rates increase likelihood of equity raises, risking dilution; SI-BONE’s cash runway and $120–150m estimated 2025 cash burn projection are under investor scrutiny.\u003c\/p\u003e\n\u003cp\u003eInvestors monitor leverage: net debt\/EBITDA and free-cash-flow trends to assess balance sheet resilience amid rate volatility.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealthcare Provider Consolidation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHospital consolidation has accelerated: in the US, 2024 saw 70% of hospitals part of systems, up from 60% in 2019, boosting buyer bargaining power and enabling volume-based discounts that compress device makers margins by an estimated 3–6 percentage points on average.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Currency Exchange Fluctuations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAs SI-BONE scales in Europe and Asia, FX volatility risks reported revenue and margins — a 10% USD appreciation vs. EUR\/JPY can cut translated revenue by roughly 5–8% for multinational medtech peers; FY2024 saw the dollar strengthen ~7% vs. euro. Strengthening USD may raise local prices, slowing uptake among international providers. SI-BONE employs hedging (forwards, options, natural hedges) to limit currency-driven earnings volatility.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eUSD up ~7% vs EUR in 2024 — potential 5–8% revenue translation hit\u003c\/li\u003e\n\u003cli\u003ePrice sensitivity may reduce adoption in Europe\/Asia\u003c\/li\u003e\n\u003cli\u003eHedging: forwards, options, and natural hedges used to stabilize margins\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConsumer Spending and Elective Procedure Volume\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpwhile si joint fusion is often clinically necessary many patients treat it as elective and may defer surgery during downturns u.s. consumer confidence fell to in oct remained subdued into correlating with reduced procedure volumes.\u003e\u003cphigh household debt-to-income reached about in q3 and medicare-aged disposable income growth slowed tying si-bone revenue to macroeconomic health aging-population spending power.\u003e\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eElective deferral risk reduces procedure volume during low confidence\u003c\/li\u003e\n\u003cli\u003eHousehold debt-to-income ~111% (Q3 2023) pressures out-of-pocket payments\u003c\/li\u003e\n\u003cli\u003eSI-BONE growth linked to disposable income trends in aging cohorts\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/phigh\u003e\u003c\/pwhile\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInflation, higher rates, FX and hospital consolidation squeeze margins and raise cash risks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eInflation raised titanium and machining costs ~10% and labor ~6% through 2025; Fed funds ~5.25–5.50% increased cost of capital; 2025 cash burn est. $120–150m risks equity raises; US hospital systemization ~70% (2024) compresses device margins 3–6%; USD strengthened ~7% vs EUR in 2024, risking 5–8% revenue translation loss; elective deferral risk persists with high household DTI ~111% (Q3 2023).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTitanium\/ machining cost rise\u003c\/td\u003e\n\u003ctd\u003e~10%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLabor cost rise\u003c\/td\u003e\n\u003ctd\u003e~6%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFed funds (late 2025)\u003c\/td\u003e\n\u003ctd\u003e5.25–5.50%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash burn est. 2025\u003c\/td\u003e\n\u003ctd\u003e$120–150m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHospitals in systems (US, 2024)\u003c\/td\u003e\n\u003ctd\u003e70%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUSD vs EUR (2024)\u003c\/td\u003e\n\u003ctd\u003e+7%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHousehold DTI (Q3 2023)\u003c\/td\u003e\n\u003ctd\u003e111%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eSame Document Delivered\u003c\/span\u003e\u003cbr\u003eSI-Bone PESTLE Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the exact document you’ll receive after purchase—fully formatted and ready to use; the SI-Bone PESTLE Analysis displayed is the real, final file with complete content, structure and professional layout. After payment you’ll instantly download this same ready-to-use analysis, no placeholders, no surprises, exactly as shown.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56751595553145,"sku":"si-bone-pestle-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/si-bone-pestle-analysis.png?v=1772233270","url":"https:\/\/matrixbcg.com\/products\/si-bone-pestle-analysis","provider":"MatrixBCG","version":"1.0","type":"link"}